The Clinigen Directors are proposing to increase the final dividend to 5.46p per share (2019: 4.75p), resulting in a 14% increase in the full year dividend to 7.61p per share (2019: 6.7p).
The final dividend will be paid, subject to shareholder approval, on 2 December 2020 to shareholders on the register on 6 November 2020.
Strong organic performance at net revenue, gross profit and EBITDA with adjusted EPS up 20% to 65.6p (2019: 54.4p)
Other financial highlights include:
Cash flows materially improved in H2, with operating cash flow conversion of 123% in H2, equating to 72% for FY20 overall
Medium term organic net revenue growth guidance of 5 - 10% - with FY21 to be at the lower end due to impact of COVID-19 and expected launch of a generic Foscavir in the EU; Foundations in place for accelerated long term growth from FY22
Trading to date at this early stage of the current financial year is in line with market expectations, with impact of COVID-19 continuing but at improved levels from Q4
